Levodopa-induced dyskinesia (LID) is an adverse effect that negatively impacts the quality
of life of patients with Parkinson's disease (PD). Studies report that genetic variations in the …

L-dopa–induced dyskinesia (LID) is a frequent motor complication of Parkinson's disease
(PD), associated with a negative prognosis. Previous studies showed an association …

L-dopa–induced dyskinesias (LID) is a common motor side effect of levodopa therapy of
Parkinson's disease (PD). The identified predictors may only partially account for the risk of …

Introduction Long-term levodopa therapy for Parkinson's disease (PD) can cause levodopa
induced dyskinesia (LID). Genetic predisposition has a significant role to play in inter …

Parkinson's disease (PD) is a multisystem disorder that affects 2–3% of the population≥ 65
years of age. The main pharmacologic agent use in the treatment of clinical symptoms of PD …

Aim: Dyskinesia and motor fluctuation are frequent and serious complications of chronic
levodopa therapy in patients with Parkinson's disease. Since genetic factors could play a …

Levodopa-induced dyskinesias (LID) present a common but elusive complication of
levodopa therapy in Parkinson's disease (PD). In order to identify genetic factors associated …

Introduction Levodopa-induced dyskinesia frequently complicates long-term Parkinson's
disease. More in-depth knowledge regarding the role of genetic factors in dyskinesia …

Introduction Levodopa-induced dyskinesia (LID) is a common motor complication in
Parkinson's disease (PD). Several genes in the levodopa metabolic pathway, such as …

Background and purpose Polymorphisms of the catechol-O-methyl transferase (COMT) or
monoamine oxidase B (MAO-B) genes may affect the occurrence of dyskinesia in …